Ashwani Verma
Stock Analyst at UBS
(3.25)
# 1,096
Out of 4,667 analysts
54
Total ratings
54.84%
Success rate
0.98%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Initiates: Neutral | $30 | $34.65 | -13.42% | 1 | Sep 19, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $56 | $32.79 | +70.78% | 1 | Sep 10, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Buy | $24 → $26 | $17.03 | +52.67% | 6 | Sep 3, 2024 | |
| CHRS Coherus BioSciences | Downgrades: Neutral | $4 → $1.5 | $1.10 | +36.36% | 4 | Aug 16, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $54 | $46.83 | +15.31% | 3 | Aug 13, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Neutral | $83 → $79 | $85.64 | -7.75% | 5 | Aug 8, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $25 → $23 | $16.27 | +41.36% | 3 | Aug 8, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $107 → $105 | $94.60 | +10.99% | 2 | Aug 6, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $300 → $370 | $364.33 | +1.56% | 3 | Jul 8, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Neutral | $117 → $113 | $119.24 | -5.23% | 5 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $26.22 | +6.79% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $174 → $193 | $123.29 | +56.54% | 4 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 → $81 | $40.14 | +101.79% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $25 | $27.91 | -10.43% | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $10.75 | +95.35% | 1 | Feb 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $61 → $92 | $49.86 | +84.52% | 4 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $52 | $87.22 | -40.38% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $103.38 | -93.23% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $13.13 | -8.61% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $2.05 | +631.71% | 1 | Oct 11, 2022 |
Exelixis
Sep 19, 2024
Initiates: Neutral
Price Target: $30
Current: $34.65
Upside: -13.42%
Harmony Biosciences Holdings
Sep 10, 2024
Initiates: Buy
Price Target: $56
Current: $32.79
Upside: +70.78%
Teva Pharmaceutical
Sep 3, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $17.03
Upside: +52.67%
Coherus BioSciences
Aug 16, 2024
Downgrades: Neutral
Price Target: $4 → $1.5
Current: $1.10
Upside: +36.36%
Biohaven
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $46.83
Upside: +15.31%
Intra-Cellular Therapies
Aug 8, 2024
Maintains: Neutral
Price Target: $83 → $79
Current: $85.64
Upside: -7.75%
ACADIA Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $25 → $23
Current: $16.27
Upside: +41.36%
Axsome Therapeutics
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $94.60
Upside: +10.99%
United Therapeutics
Jul 8, 2024
Maintains: Buy
Price Target: $300 → $370
Current: $364.33
Upside: +1.56%
Jazz Pharmaceuticals
Jul 2, 2024
Maintains: Neutral
Price Target: $117 → $113
Current: $119.24
Upside: -5.23%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $26.22
Upside: +6.79%
May 28, 2024
Maintains: Buy
Price Target: $174 → $193
Current: $123.29
Upside: +56.54%
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $40.14
Upside: +101.79%
Feb 20, 2024
Downgrades: Sell
Price Target: $25
Current: $27.91
Upside: -10.43%
Feb 6, 2024
Initiates: Buy
Price Target: $21
Current: $10.75
Upside: +95.35%
Jan 24, 2024
Downgrades: Neutral
Price Target: $61 → $92
Current: $49.86
Upside: +84.52%
Oct 17, 2023
Initiates: Buy
Price Target: $52
Current: $87.22
Upside: -40.38%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $103.38
Upside: -93.23%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $13.13
Upside: -8.61%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $2.05
Upside: +631.71%